About NeurogesX (OTCMKTS:NGSX)
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pains management therapies to address unmet medical needs. Qutenza is the Company's first commercial product, available in the United States and in certain European countries. Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions and was approved by the food and drugs administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia (PHN). Qutenza is also approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults. The Company's advanced drug candidate is NGX-1998. NGX-1998 is a topical liquid formulation of high concentration capsaicin that the Company is developing to treat neuropathic pain conditions.
Industry, Sector and Symbol
Trailing P/E Ratio-0.00510204081632653
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on Assets-68.56%
NeurogesX (OTCMKTS:NGSX) Frequently Asked Questions
What is NeurogesX's stock symbol?
NeurogesX trades on the OTCMKTS under the ticker symbol "NGSX."
Who are some of NeurogesX's key competitors?
Some companies that are related to NeurogesX include Baxano Surgical (BAXSQ), Savient Pharmaceuticals (SVNTQ), NephroGenex (NRXGQ), Air Methods (AIRM), Alexza Pharmaceuticals (ALXA), Allos Therapeutics (ALTH), Ambit Biosciences (AMBI), Amgen Rockville (MITI), Amylin Pharmaceuticals (AMLN), Ardea Biosciences (RDEA), Ariad Pharmaceuticals (ARIA), ArthroCare (ARTC), Asante Solutions (PUMP), Avanir Pharmaceuticals (AVNR), Baxalta (BXLT), Bayer Essure (CPTS), BioMimetic Therapeutics (BMTI) and Bio-Reference Laboratories (BRLI).
How do I buy NeurogesX stock?
Shares of NeurogesX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeurogesX's stock price today?
One share of NeurogesX stock can currently be purchased for approximately $0.01.
How big of a company is NeurogesX?
NeurogesX has a market capitalization of $129,628.00.
How can I contact NeurogesX?
NeurogesX's mailing address is 2215 Bridgepointe Pkwy Ste 200, FOSTER CITY, CA 94404-5067, United States. The specialty pharmaceutical company can be reached via phone at +1-650-3583300.
MarketBeat Community Rating for NeurogesX (NGSX)MarketBeat's community ratings are surveys of what our community members think about NeurogesX and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
NeurogesX (OTCMKTS:NGSX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
NeurogesX (OTCMKTS:NGSX) Earnings History and Estimates Chart
NeurogesX (OTCMKTS NGSX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
NeurogesX (OTCMKTS:NGSX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for NeurogesX (OTCMKTS:NGSX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for NeurogesX (OTCMKTS NGSX)
No insider trades for this company have been tracked by MarketBeat.com
NeurogesX (OTCMKTS NGSX) News Headlines
No headlines for this company have been tracked by MarketBeat.com
NeurogesX (OTCMKTS:NGSX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NeurogesX (OTCMKTS:NGSX) Income Statement, Balance Sheet and Cash Flow Statement
NeurogesX (OTCMKTS NGSX) Stock Chart for Saturday, February, 17, 2018